Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23167577 | 1.00 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL23165638 | 1.00 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL23167590 | 1.00 | GLB1 (0.38) | GLB1GBA1 | |
| SCHEMBL4373139 | 0.83 | GLB1 (0.34) | GLB1GBA1 | |
| SCHEMBL15601207 | 0.83 | — | — | |
| SCHEMBL20615406 | 0.83 | — | — | |
| SCHEMBL20615408 | 0.83 | — | — | |
| SCHEMBL18583340 | 0.83 | — | — | |
| SCHEMBL15533438 | 0.83 | GLB1 (0.40) | GLB1GBA1 | |
| SCHEMBL6401642 | 0.81 | GLB1 (0.39) | GLB1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200197382-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | GLB1 1592/4885GBA1 261/4885 |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | GLB1 393/4885GBA1 298/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | GLB1 557/4885GBA1 2785/4885 |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | GLB1 144/4885GBA1 471/4885 |
| US-20200197382-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | GLB1 196/4885GBA1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.